Glenmark Pharma gets USFDA nod for acne treatment drug
The approved product is a generic version of Cleocin T Gel, 1 per cent, of Pharmacia Upjohn.11-02-2021
11-02-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Gel USP, 1%11-02-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Update on board meeting
GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2021 ,inter alia, to consider and approve Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to consider repurchase of Foreign Currency Debt09-02-2021
Glenmark Pharma gets USFDA nod for seizure treatment drug
The approved product is a generic version of Qudexy XR Capsules of Upsher-Smith Laboratories, LLC.03-02-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA approval for Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg03-02-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed Notice of the Board Meeting published in newspapers viz. the Free Press Journal and Navshakti on February 2, 2021.02-02-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed please find herewith the details of Earnings Call slated for Monday, February 15, 2021 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.01-02-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Closure of Trading Window
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, February 12, 2021, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2020. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from December 31, 2020 to February 14, 2021 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2020.01-02-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Board Meeting Intimation for Unaudited Financial Results Of The Company For The Third Quarter And Nine Months Ended December 31, 2020.
GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2021 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2020. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from December 31, 2020 to February 14, 2021 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2020.01-02-2021
Glenmark Pharma share price rises on US FDA final approval
The share touched its 52-week high Rs 572.70 and 52-week low Rs 168 on 22 June, 2020 and 13 March, 2020, respectively.28-01-2021